DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
DaVita Divests DMG to Optum, Boosts Kidney Care Services
by Zacks Equity Research
The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.
Why Is DaVita HealthCare (DVA) Down 9.9% Since Last Earnings Report?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain DaVita (DVA) in Your Portfolio
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.
DaVita (DVA) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
DaVita (DVA) gains from international revenues in Q1.
DaVita HealthCare (DVA) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -4.21% and -2.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.
Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.
Fresenius Medical's New Hemodialysis Software Gets FDA Nod
by Zacks Equity Research
Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.
Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
by Zacks Equity Research
Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.
DaVita HealthCare (DVA) Down 7.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Consider DaVita (DVA) Stock Now?
by Zacks Equity Research
Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.
Here's Why Investors Should Hold DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.
New Strong Sell Stocks for February 19th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Stock Market News For Feb 14, 2019
by Zacks Equity Research
Wall Street rally continued in Wednesday buoyed by positive developments on the trade war front.
DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates
by Zacks Equity Research
DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.
DaVita HealthCare (DVA) Tops Q4 Earnings Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 1.12% and -5.73%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects headwinds in DaVita Rx, while overseas prospects of the dialysis business look bright.
Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) Gains From Sharesource's Global Success Rates
by Zacks Equity Research
Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.
Baxter's PD Solution to Treat Patients, Prospects Bright
by Zacks Equity Research
Baxter's (BAX) kidney care portfolio likely to favor the company as kidney care demand shoots up in the United States.
DaVita HealthCare (DVA) Down 11.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Falling Estimates & Price Mean for DaVita (DVA)
by Zacks Equity Research
DaVita (DVA) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Bright Outlook for Outpatient and Home Healthcare Industry
by Zacks Equity Research
Here we discuss how outpatient and home healthcare have been creating opportunities for investors keen on parking their money in this space.